KURA ONCOLOGY, INC. Interest Paid, Including Capitalized Interest, Operating and Investing Activities
KURA ONCOLOGY, INC. (KURA) reported Interest Paid, Including Capitalized Interest, Operating and Investing Activities of $627.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-12.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:InterestPaid · last filed 2018-03-12
- KURA ONCOLOGY, INC. interest paid, including capitalized interest, operating and investing activities for the quarter ending 2017-12-31 was $161.00K, a 9.52% increase year-over-year.
- KURA ONCOLOGY, INC. interest paid, including capitalized interest, operating and investing activities for the quarter ending 2017-09-30 was $161.00K, a 8.78% increase year-over-year.
- KURA ONCOLOGY, INC. interest paid, including capitalized interest, operating and investing activities for the quarter ending 2017-06-30 was $157.00K.
- KURA ONCOLOGY, INC. interest paid, including capitalized interest, operating and investing activities for the quarter ending 2017-03-31 was $148.00K.
- KURA ONCOLOGY, INC. interest paid, including capitalized interest, operating and investing activities for fiscal 2017 was $627.00K, a 78.13% increase from fiscal 2016.
- KURA ONCOLOGY, INC. interest paid, including capitalized interest, operating and investing activities for fiscal 2016 was $352.00K.
| Period end | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 3 month | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 6 month | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 9 month | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $161.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $322.00K derived: sum of 2 quarters · filed 2018-03-12 | $479.00K derived: sum of 3 quarters · filed 2018-03-12 | $627.00K 10-K · filed 2018-03-12 |
| 2017-09-30 | $161.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $318.00K derived: sum of 2 quarters · filed 2017-11-07 | $466.00K 10-Q · filed 2017-11-07 | $613.00K derived: sum of 4 quarters · filed 2018-03-12 |
| 2017-06-30 | $157.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $305.00K 10-Q · filed 2017-08-07 | $452.00K derived: sum of 3 quarters · filed 2018-03-12 | $600.00K derived: sum of 4 quarters · filed 2018-03-12 |
| 2017-03-31 | $148.00K 10-Q · filed 2017-05-15 | $295.00K derived: sum of 2 quarters · filed 2018-03-12 | $443.00K derived: sum of 3 quarters · filed 2018-03-12 | |
| 2016-12-31 | $147.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $295.00K derived: sum of 2 quarters · filed 2018-03-12 | $352.00K 10-K · filed 2018-03-12 | |
| 2016-09-30 | $148.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $205.00K 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $57.00K 10-Q · filed 2017-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |